本研究將探討以glofitamab為基礎的治療在復發性或難治性擴散性大B細胞淋巴瘤(R/R DLBCL)的中國成人參與者中的有效性和安全性。
適應症：Diffuse Large B-Cell Lymphoma
收案條件
納入條件
- Histologically confirmed R/R DLBCL after one line of systemic therapy
- Will be treated with Glofit-based regimen (known as being recommended and having the intention to be treated with Glofitamab at the time of signing ICF) or have initiated Glofit-based regimen treatment within three months (90 days) prior to enrollment
排除條件
- Participants who currently participate in or plan to participate in any interventional clinical trial
收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。